Study Of Lymphoma Drug, Inotuzumab Ozogamicin, Halted Since It's Unlikely To Help Survival
The study tested inotuzumab in combination with Roche Holding's Rituxan in patients with relapsed or refractory aggressive
study lymphoma drug inotuzumab ozogamicin halt unlikely help survival study test inotuzumab combination roche holding rituxan patient relapsed refractory aggressive